ProstaLund

Third quarter

July 1 - September 30

• Net sales reached SEK 3,5 million (4,8)
• Operating profit/loss totaled SEK -4,4 million (-6,2)
• Loss after taxes SEK -4,5 million (-6,3)
• Earnings per share, SEK before and after dilution amounted to SEK -0,04 (-0,08)
• Cash flow from operating activities amounted to SEK -3,4 million (-11,9)

January 1 - September 30

• Net sales reached SEK 9,8 million (10,9)
• Operating profit/loss totaled SEK -16,3 million (-13,4)
• Loss after taxes SEK -16,5 million (-13,5)
• Earnings per share, SEK before and after dilution amounted SEK -0,18 (-0,21)
• Cash flow from operating activities amounted to SEK -16,1 million (-17,9)
• Cash and cash equivalents amounted to SEK 12,1 million (22,5)

Significant events during the period

• On July 3, ProstaLund announced that it is carrying out a directed issue of units to the guarantor in connection with the completed rights issue.
• ProstaLund informed on July 11 to return with an announcement last day of trading in BTU after the rights issue has been registered.
• ProstaLund announced on July 17 the last day of trading in BTUs and first day of trading in warrants of series TO 3.
• First patients treated with CoreTherm® Concept in Austria.
• Published study confirms the good effect of transurethral intraprostatic anesthesia (TUIA) via Schelin Catheter®.
• Prostalund’s CEO and CFO have acquired shares and warrants.

Significant events after the end of the period

• First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate.
• Short-term results and long-term durability after CoreTherm® treatments pre- sented at the Emirates International Urological Conference in Dubai, UAE.
• Notice of Extraordinary General Meeting regarding decision on reverse share split.

Key figures